Most Read Articles
Elaine Soliven, 4 days ago

Switching from efavirenz/emtricitabine/tenofovir disoproxil fumarate (EFV/FTC/TDF) to the new bictegravir/ emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) regimen maintained high rates of virological suppression in adults who are living with HIV*, according to a study presented at AIDS 2020.

3 days ago
Among individuals with abdominal obesity, drinking beverages with artificial sweeteners (ASBs) or no sugar (USBs) instead of sugar-sweetened beverages (SSBs) helps lose body weight, a study has found. However, USBs have a more favourable effect on sweet taste preference compared with ASBs.
Stephen Padilla, 5 days ago
Pre-exposure prophylaxis (PrEP) containing either long-acting injectable cabotegravir (CAB) or tenofovir/emtricitabine (TDF/FTC) is safe and effective for transgender women (TGW) and cisgender men who have sex with men (MSM), but CAB results in a much lower HIV incidence compared to TDF/FTC, results of the HIV Prevention Trials Network (HPTN) 083 have shown.
Jairia Dela Cruz, 4 days ago
Monthly prophylaxis with the fixed-dose combination of naphthoquine-azithromycin (NQAZ) is well tolerated and confers significant protection against infection with Plasmodium parasites among individuals residing in malaria-endemic areas in Southeast Asia, as shown in the results of a phase III trial.

Weight-loss surgery helps resolve nonalcoholic steatohepatitis

26 Jun 2020

Bariatric surgery may lead to the resolution of nonalcoholic steatohepatitis (NASH) with a sustained reduction in fibrosis over 5 years, as shown in a study.

Researchers followed for 5 years a total of 180 severely obese patients (mean age, 46.7 years; median fibrosis score, 2) with biopsy-proven NASH who underwent bariatric surgery (66.1 percent had gastric bypass). Three patients died from non-liver-related causes: two from surgical complications within the first month after surgery and one from cardiac dysfunction at the 4-year follow-up.

Liver biopsies were obtained from 125 of 169 patients (76 percent) in the first year of follow-up and from 64 of 94 patients (68 percent) at the fifth year. Histological evaluation was not available in some patients mainly because of biopsy refusal.

At 5 years after weight-loss surgery, 84 percent of patients achieved the primary endpoint of resolution of NASH without worsening of fibrosis. Moreover, fibrosis decreased from baseline in 70.2 percent of patients. It disappeared in biopsy samples from 56 percent of all patients, as well as in samples from 45.5 percent of those with baseline bridging fibrosis.

NASH persistence was predicted by a lack of fibrosis reduction and less weight loss (mean reduction in body mass index, –6.3 vs –13.4 kg/m2 in patients with persistent vs resolved NASH, respectively; p=0.017).

NASH resolution was observed at 1 year post-bariatric surgery in biopsies from 84 percent of patients, with no significant recurrence between 1 and 5 years (p=0.17). Finally, reductions in fibrosis started to occur by 1 year and continued until 5 years (p<0.001).

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Hepatology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Elaine Soliven, 4 days ago

Switching from efavirenz/emtricitabine/tenofovir disoproxil fumarate (EFV/FTC/TDF) to the new bictegravir/ emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) regimen maintained high rates of virological suppression in adults who are living with HIV*, according to a study presented at AIDS 2020.

3 days ago
Among individuals with abdominal obesity, drinking beverages with artificial sweeteners (ASBs) or no sugar (USBs) instead of sugar-sweetened beverages (SSBs) helps lose body weight, a study has found. However, USBs have a more favourable effect on sweet taste preference compared with ASBs.
Stephen Padilla, 5 days ago
Pre-exposure prophylaxis (PrEP) containing either long-acting injectable cabotegravir (CAB) or tenofovir/emtricitabine (TDF/FTC) is safe and effective for transgender women (TGW) and cisgender men who have sex with men (MSM), but CAB results in a much lower HIV incidence compared to TDF/FTC, results of the HIV Prevention Trials Network (HPTN) 083 have shown.
Jairia Dela Cruz, 4 days ago
Monthly prophylaxis with the fixed-dose combination of naphthoquine-azithromycin (NQAZ) is well tolerated and confers significant protection against infection with Plasmodium parasites among individuals residing in malaria-endemic areas in Southeast Asia, as shown in the results of a phase III trial.